The interplay of gut microbiota, obesity, and depression: insights and interventions.
Antidepressants
Depression
Gut microbiota
Mental health
Obesity
Probiotics
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
30
07
2024
accepted:
07
10
2024
revised:
08
09
2024
medline:
31
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The gut microbiome, body weight, and related comorbidities are intricately linked through a complex interaction of microbial, genetic, environmental, and psychological factors. Alterations in gut microbiota can contribute to the development of weight disorders and depressive symptoms, with the potential for these relationships to be bidirectional. Effective management of these interconnected conditions often involves a combination of lifestyle modifications and psychological support. Medical interventions, including treatments for obesity, antidiabetic drugs, antidepressants, antibiotics, and probiotics, can have beneficial and detrimental effects on gut microbiota and mental health. Further research is needed to better understand their impact on gut microbiome and mental health in the context of obesity.
Identifiants
pubmed: 39476179
doi: 10.1007/s00018-024-05476-w
pii: 10.1007/s00018-024-05476-w
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
443Informations de copyright
© 2024. The Author(s).
Références
Carmody RN, Bisanz JE (2023) Roles of the gut microbiome in weight management. Nat Rev Microbiol 21(8):535–550
pubmed: 37138047
doi: 10.1038/s41579-023-00888-0
Gou W, Miao Z, Deng K, Zheng JS (2023) Nutri-Microbiome epidemiology, an emerging field to disentangle the interplay between nutrition and microbiome for human health. Protein Cell 14(11):787–806
pubmed: 37099800
pmcid: 10636640
doi: 10.1093/procel/pwad023
Behzadi P, Dodero VI, Golubnitschaja O (2024) Systemic inflammation as the Health-Related Communication Tool between the Human Host and gut microbiota in the Framework of Predictive, Preventive, and Personalized Medicine. All around Suboptimal Health: Advanced approaches by Predictive, Preventive and Personalised Medicine for healthy populations. Springer, pp 203–241
Lathakumari RH, Vajravelu LK, Satheesan A, Ravi S, Thulukanam J (2024) Antibiotics and the gut microbiome: understanding the impact on human health. Med Microecology. :100106
Mukherjee S, Patra R, Behzadi P, Masotti A, Paolini A, Sarshar M (2023) Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives. Front Immunol 14:1244345
pubmed: 37822929
pmcid: 10562563
doi: 10.3389/fimmu.2023.1244345
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC (2019) What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7(1):14
pubmed: 30634578
pmcid: 6351938
doi: 10.3390/microorganisms7010014
Behzadi P, Najafi A, Behzadi E, Ranjbar R (2016) Microarray long oligo probe designing for Escherichia coli: an in-silico DNA marker extraction. Cent Eur J Urol 69(1):105
Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A (2019) Obesity programs of nutrition E, Research, group A. Gut microbiota: a new path to treat obesity. Int J Obes Supplements 9(1):10–19
doi: 10.1038/s41367-019-0011-7
Montenegro J, Armet AM, Willing BP, Deehan EC, Fassini PG, Mota JF, Walter J, Prado CM (2023) Exploring the influence of gut microbiome on energy metabolism in humans. Adv Nutr 14(4):840–857
pubmed: 37031749
pmcid: 10334151
doi: 10.1016/j.advnut.2023.03.015
Li Z, Yi C-X, Katiraei S, Kooijman S, Zhou E, Chung CK, Gao Y, van den Heuvel JK, Meijer OC, Berbée JF (2018) Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut 67(7):1269–1279
pubmed: 29101261
doi: 10.1136/gutjnl-2017-314050
de Wit DF, Hanssen NMJ, Wortelboer K, Herrema H, Rampanelli E, Nieuwdorp M (2023) Evidence for the contribution of the gut microbiome to obesity and its reversal. Sci Transl Med 15(723):eadg2773
pubmed: 37992156
doi: 10.1126/scitranslmed.adg2773
Van Hul M, Cani PD (2023) The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Reviews Endocrinol 19(5):258–271
doi: 10.1038/s41574-022-00794-0
Kemp JVA, Kumar V, Saleem A, Hashman G, Hussain M, Taylor VH (2023) Examining associations between women’s Mental Health and obesity. Psychiatr Clin North Am 46(3):539–549
pubmed: 37500249
doi: 10.1016/j.psc.2023.04.009
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo G, De Graaf R, Demyttenaere K, Hu C, Iwata N (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9:1–16
doi: 10.1186/1741-7015-9-90
Radjabzadeh D, Bosch JA, Uitterlinden AG, Zwinderman AH, Ikram MA, van Meurs JB, Luik AI, Nieuwdorp M, Lok A, van Duijn CM (2022) Gut microbiome-wide association study of depressive symptoms. Nat Commun 13(1):7128
pubmed: 36473852
pmcid: 9726982
doi: 10.1038/s41467-022-34502-3
(WHO) WHO, Depression, WHO (2024); [ https://www.who.int/health-topics/depression#tab=tab_2
Ferrari S, Mulè S, Parini F, Galla R, Ruga S, Rosso G, Brovero A, Molinari C, Uberti F (2024) The influence of the gut-brain axis on anxiety and depression: a review of the literature on the use of probiotics. J Traditional Complement Med
Luqman A, He M, Hassan A, Ullah M, Zhang L, Rashid Khan M, Din AU, Ullah K, Wang W, Wang G (2024) Mood and microbes: a comprehensive review of intestinal microbiota’s impact on depression. Front Psychiatry 15
Turecki G, Brent DA, Gunnell D, O’Connor RC, Oquendo MA, Pirkis J, Stanley BH (2019) Suicide and suicide risk. Nat Reviews Disease Primers 5(1):74
pubmed: 31649257
doi: 10.1038/s41572-019-0121-0
Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) Obesity alters gut microbial ecology. Proceedings of the national academy of sciences 102(31):11070-5
Ryan PM, Patterson E, Carafa I, Mandal R, Wishart DS, Dinan TG, Cryan JF, Tuohy KM, Stanton C, Ross RP (2020) Metformin and Dipeptidyl Peptidase-4 inhibitor differentially modulate the intestinal microbiota and plasma metabolome of metabolically dysfunctional mice. Can J Diabetes 44(2):146–55e2
pubmed: 31445961
doi: 10.1016/j.jcjd.2019.05.008
Rigoulet M, Bouchez CL, Paumard P, Ransac S, Cuvellier S, Duvezin-Caubet S, Mazat JP, Devin A (2020) Cell energy metabolism: an update. Biochim et Biophys Acta (BBA)-Bioenergetics 1861(11):148276
pubmed: 32717222
doi: 10.1016/j.bbabio.2020.148276
Galgani J, Ravussin E (2008) Energy metabolism, fuel selection and body weight regulation. Int J Obes 32(7):S109–S19
doi: 10.1038/ijo.2008.246
Hjorth MF, Roager HM, Larsen TM, Poulsen S, Licht TR, Bahl MI, Zohar Y, Astrup A (2018) Pre-treatment microbial Prevotella-to-Bacteroides ratio, determines body fat loss success during a 6-month randomized controlled diet intervention. Int J Obes 42(3):580–583
doi: 10.1038/ijo.2017.220
Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Kiilerich P, Roager HM, Kristiansen K, Larsen LH, Astrup A (2019) Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis. Int J Obes 43(1):149–157
doi: 10.1038/s41366-018-0093-2
Behzadi P, Kim C-H, Pawlak EA, Algammal A (2023) The innate and adaptive immune system in human urinary system. Front Immunol 14:1294869
pubmed: 37876936
pmcid: 10593411
doi: 10.3389/fimmu.2023.1294869
Wang M, Song Z, Lai S, Tang F, Dou L, Yang F (2024) Depression-associated gut microbes, metabolites and clinical trials. Front Microbiol 15:1292004
pubmed: 38357350
pmcid: 10864537
doi: 10.3389/fmicb.2024.1292004
McGuinness A, Davis JA, Dawson S, Loughman A, Collier F, O’hely M, Simpson C, Green J, Marx W, Hair C (2022) A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry 27(4):1920–1935
pubmed: 35194166
pmcid: 9126816
doi: 10.1038/s41380-022-01456-3
Zang Y, Lai X, Li C, Ding D, Wang Y, Zhu Y (2023) The role of gut microbiota in various Neurological and Psychiatric Disorders-An evidence mapping based on quantified evidence. Mediat Inflamm 2023:5127157
doi: 10.1155/2023/5127157
George F, Daniel C, Thomas M, Singer E, Guilbaud A, Tessier FJ, Revol-Junelles A-M, Borges F, Foligné B (2018) Occurrence and dynamism of lactic acid bacteria in distinct ecological niches: a multifaceted functional health perspective. Front Microbiol 9:2899
pubmed: 30538693
pmcid: 6277688
doi: 10.3389/fmicb.2018.02899
Giménez-Palomo A, Dodd S, Anmella G, Carvalho AF, Scaini G, Quevedo J, Pacchiarotti I, Vieta E, Berk M (2021) The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment. Front Psychiatry 12:546801
pubmed: 34295268
pmcid: 8291901
doi: 10.3389/fpsyt.2021.546801
Larrea A, Sánchez-Sánchez L, Diez-Martin E, Elexpe A, Torrecilla M, Astigarraga E, Barreda-Gómez G (2024) Mitochondrial metabolism in major depressive disorder: from early diagnosis to Emerging Treatment options. J Clin Med 13(6):1727
pubmed: 38541952
pmcid: 10971738
doi: 10.3390/jcm13061727
Steffen J, Focken N, Çalışkan G (2024) Recognizing depression as an inflammatory disease: the search for endotypes. Am J Physiol Cell Physiol 327(1):C205–c12
pubmed: 38826138
doi: 10.1152/ajpcell.00246.2024
Gardiner JV, Jayasena CN, Bloom SR (2008) Gut hormones: a weight off your mind. J Neuroendocrinol 20(6):834–841
pubmed: 18601707
doi: 10.1111/j.1365-2826.2008.01729.x
Steptoe A, Frank P (2023) Obesity and psychological distress. Philosophical Trans Royal Soc Lond Ser B Biol Sci 378(1888):20220225
doi: 10.1098/rstb.2022.0225
Song EJ, Shin NR, Jeon S, Nam YD, Kim H (2022) Lorcaserin and phentermine exert anti-obesity effects with modulation of the gut microbiota. Front Microbiol 13:1109651
pubmed: 36687627
doi: 10.3389/fmicb.2022.1109651
Pati B, Sendh S, Sahu B, Pani S, Jena N, Bal NC (2023) Recent advancements in pharmacological strategies to modulate energy balance for combating obesity. RSC Med Chem 14(8):1429–1445
pubmed: 37593583
pmcid: 10429841
doi: 10.1039/D3MD00107E
Lee CJ, Sears CL, Maruthur N (2020) Gut microbiome and its role in obesity and insulin resistance. Ann N Y Acad Sci 1461(1):37–52
pubmed: 31087391
doi: 10.1111/nyas.14107
Wu L, Ye S, Deng X, Fu Z, Li J, Yang C (2024) Conjugated linoleic acid ameliorates high Fat-Induced insulin resistance via regulating gut microbiota-host metabolic and immunomodulatory interactions. Nutrients; 16(8)
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S (2024) Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet (London England) 403(10434):e21–e31
pubmed: 38582569
doi: 10.1016/S0140-6736(24)00351-9
Boggio Marzet C, Burgos F, Del Compare M, Gerold I, Tabacco O, Vinderola G (2022) Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. Arch Argentinos De Pediatria 120(1):e1–e7
Mills S, Yang B, Smith GJ, Stanton C, Ross RP (2023) Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond. Gut Microbes 15(1):2186098
pubmed: 36896934
pmcid: 10012958
doi: 10.1080/19490976.2023.2186098
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I (2021) Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London England) 397(10278):971–984
pubmed: 33667417
doi: 10.1016/S0140-6736(21)00213-0
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D (2021) Effect of continued Weekly Subcutaneous Semaglutide vs Placebo on Weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA 325(14):1414–1425
pubmed: 33755728
doi: 10.1001/jama.2021.3224
Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J (2024) Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochem Biophys Res Commun 710:149882
pubmed: 38583231
doi: 10.1016/j.bbrc.2024.149882
Xiong C, Wu J, Ma Y, Li N, Wang X, Li Y, Ding X (2024) Effects of Glucagon-Like Peptide-1 receptor agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome mice: compared evaluation of Liraglutide and Semaglutide intervention. Diabetes Metabolic Syndrome Obesity: Targets Therapy 17:865–880
pubmed: 38406269
doi: 10.2147/DMSO.S451129
de Paiva IHR, da Silva RS, Mendonça IP, de Souza JRB, Peixoto CA (2024) Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacology: Official J Soc NeuroImmune Pharmacol 19(1):36
doi: 10.1007/s11481-024-10142-w
Ying X, Rongjiong Z, Kahaer M, Chunhui J, Wulasihan M (2023) Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease. Front Microbiol 14:1088187
pubmed: 36778868
pmcid: 9909237
doi: 10.3389/fmicb.2023.1088187
Tobaiqy M, Elkout H (2024) Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int J Clin Pharm 46(2):488–495
pubmed: 38265519
pmcid: 10960895
doi: 10.1007/s11096-023-01694-7
Tagliapietra GA, Cantrell MA, Lund BC (2024) Glucagon-like peptide receptor agonists and risk for depression. Prim Care Diabetes
Arillotta D, Floresta G, Guirguis A, Corkery JM, Catalani V, Martinotti G, Sensi SL, Schifano F (2023) GLP-1 receptor agonists and related Mental Health issues; insights from a range of Social Media platforms using a mixed-methods Approach. Brain Sci.; 13(11)
Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER 3rd, Appel LJ, Yeh HC (2021) Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a Randomized Trial. Diabetes Care 44(7):1462–1471
pubmed: 34006565
pmcid: 8323185
doi: 10.2337/dc20-2257
Rosell-Díaz M, Petit-Gay A, Molas-Prat C, Gallardo-Nuell L, Ramió-Torrentà L, Garre-Olmo J, Pérez-Brocal V, Moya A, Jové M, Pamplona R, Puig J, Ramos R, Bäckhed F, Mayneris-Perxachs J, Fernández-Real JM (2024) Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men. Metab Clin Exp 157:155941
pubmed: 38871078
doi: 10.1016/j.metabol.2024.155941
Petakh P, Kobyliak N, Kamyshnyi A (2023) Gut microbiota in patients with COVID-19 and type 2 diabetes: a culture-based method. Front Cell Infect Microbiol 13:1142578
pubmed: 36844398
pmcid: 9947359
doi: 10.3389/fcimb.2023.1142578
Kessing LV, Rytgaard HC, Ekstrøm CT, Knop FK, Berk M, Gerds TA (2020) Antidiabetes agents and Incident Depression: a Nationwide Population-based study. Diabetes Care 43(12):3050–3060
pubmed: 32978179
doi: 10.2337/dc20-1561
Yu H, Yang R, Wu J, Wang S, Qin X, Wu T, Hu Y, Wu Y (2022) Association of metformin and depression in patients with type 2 diabetes. J Affect Disord 318:380–385
pubmed: 36108876
doi: 10.1016/j.jad.2022.09.015
Raineri S, Sherriff JA, Thompson KSJ, Jones H, Pfluger PT, Ilott NE, Mellor J (2022) Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats. BMC Microbiol 22(1):91
pubmed: 35392807
pmcid: 8988407
doi: 10.1186/s12866-022-02494-1
Uehira Y, Ueno H, Miyamoto J, Kimura I, Ishizawa Y, Iijima H, Muroga S, Fujita T, Sakai S, Samukawa Y, Tanaka Y, Murayama S, Sakoda H, Nakazato M (2023) Impact of the lipase inhibitor orlistat on the human gut microbiota. Obes Res Clin Pract 17(5):411–420
pubmed: 37679239
doi: 10.1016/j.orcp.2023.08.005
Thai K, Taylor MW, Fernandes T, Akinade EA, Campbell SL (2023) Topiramate alters the gut microbiome to aid in its anti-seizure effect. Front Microbiol 14:1242856
pubmed: 37942078
pmcid: 10629356
doi: 10.3389/fmicb.2023.1242856
Deng L, Yang Y, Xu G (2022) Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochim et Biophys acta Mol cell Biology Lipids 1867(12):159234
doi: 10.1016/j.bbalip.2022.159234
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R (2022) Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: Randomized double-blind placebo-controlled trial. Am J Psychiatry 179(12):927–937
pubmed: 36285406
pmcid: 9722598
doi: 10.1176/appi.ajp.20220267
Grilo CM, Kerrigan SG, Lydecker JA, White MA (2021) Physical activity changes during behavioral weight loss treatment by Latinx patients with obesity with and without binge eating disorder. Obes (Silver Spring Md) 29(12):2026–2034
doi: 10.1002/oby.23278
Kolotkin RL, Gadde KM, Peterson CA, Crosby RD (2016) Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: what mediates improvement? Qual life Research: Int J Qual life Aspects Treat care Rehabilitation 25(5):1237–1244
doi: 10.1007/s11136-015-1153-x
Şahin S, Haliloğlu Ö, Polat Korkmaz Ö, Durcan E, Rekalı Şahin H, Yumuk VD, Damcı T, İlkova HM, Oşar Siva Z (2020) Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with type 2 diabetes mellitus? Turk J Med Sci 51(2):735–742
pubmed: 33356033
doi: 10.3906/sag-2008-37
He L, Fu Y, Tian Y, Wang X, Zhou X, Ding RB, Qi X, Bao J (2023) Antidepressants as Autophagy modulators for Cancer Therapy. Molecules; 28(22)
Chen T, Cheng L, Ma J, Yuan J, Pi C, Xiong L, Chen J, Liu H, Tang J, Zhong Y, Zhang X, Liu Z, Zuo Y, Shen H, Wei Y, Zhao L (2023) Molecular mechanisms of rapid-acting antidepressants: new perspectives for developing antidepressants. Pharmacol Res 194:106837
pubmed: 37379962
doi: 10.1016/j.phrs.2023.106837
Rukavishnikov G, Leonova L, Kasyanov E, Leonov V, Neznanov N, Mazo G (2023) Antimicrobial activity of antidepressants on normal gut microbiota: results of the in vitro study. Front Behav Neurosci 17:1132127
pubmed: 37035624
pmcid: 10073483
doi: 10.3389/fnbeh.2023.1132127
Xu F, Xie Q, Kuang W, Dong Z (2023) Interactions between antidepressants and Intestinal Microbiota. Neurotherapeutics: J Am Soc Experimental Neurother 20(2):359–371
doi: 10.1007/s13311-023-01362-8